Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit

Fuente: Wiley Open Access
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zoe Garoufalia, Sameh Hany Emile, Justin Dourado, Marylise Boutros, Richard Brady, Valerio Celentano, Justin Davies, Phillip R. Fleshner, Rachel Gefen, Stefan D. Holubar, Nir Horesh, Alaa El‐Hussuna, Deborah Keller, Amy Lightner, Gianluca Pellino, Sherief Shawki, Spyros Siakavellas, Antonino Spinelli, Janindra Warusavitarne, Steven D. Wexner
Format: Artículo Open Access
Veröffentlicht: Wiley 2025
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867018946832498688
author Zoe Garoufalia
Sameh Hany Emile
Justin Dourado
Marylise Boutros
Richard Brady
Valerio Celentano
Justin Davies
Phillip R. Fleshner
Rachel Gefen
Stefan D. Holubar
Nir Horesh
Alaa El‐Hussuna
Deborah Keller
Amy Lightner
Gianluca Pellino
Sherief Shawki
Spyros Siakavellas
Antonino Spinelli
Janindra Warusavitarne
Steven D. Wexner
author_facet Zoe Garoufalia
Sameh Hany Emile
Justin Dourado
Marylise Boutros
Richard Brady
Valerio Celentano
Justin Davies
Phillip R. Fleshner
Rachel Gefen
Stefan D. Holubar
Nir Horesh
Alaa El‐Hussuna
Deborah Keller
Amy Lightner
Gianluca Pellino
Sherief Shawki
Spyros Siakavellas
Antonino Spinelli
Janindra Warusavitarne
Steven D. Wexner
Zoe Garoufalia
Sameh Hany Emile
Justin Dourado
Marylise Boutros
Richard Brady
Valerio Celentano
Justin Davies
Phillip R. Fleshner
Rachel Gefen
Stefan D. Holubar
Nir Horesh
Alaa El‐Hussuna
Deborah Keller
Amy Lightner
Gianluca Pellino
Sherief Shawki
Spyros Siakavellas
Antonino Spinelli
Janindra Warusavitarne
Steven D. Wexner
collection Wiley Open Access
contents Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit Zoe Garoufalia Sameh Hany Emile Justin Dourado Marylise Boutros Richard Brady Valerio Celentano Justin Davies Phillip R. Fleshner Rachel Gefen Stefan D. Holubar Nir Horesh Alaa El‐Hussuna Deborah Keller Amy Lightner Gianluca Pellino Sherief Shawki Spyros Siakavellas Antonino Spinelli Janindra Warusavitarne Steven D. Wexner Colorectal Disease AbstractBackgroundInflammatory bowel disease (IBD) affects more than 10 million people worldwide. Men and women are equally affected by Crohn's disease (CD). It has been shown that patients with CD are at an increased risk of a colorectal cancer (CRC) diagnosis and CRC‐related mortality. During the last two decades, biological therapies have revolutionized the treatment of CD. There are no current studies investigating the prevalence of CRC in patients with CD in the era of biological therapy and the possible features of patients with CD who are at high risk of developing CRC.AimWe aim to assess the prevalence of CRC, risk factors and profile of CRC in patients with CD receiving biological treatment compared with those who are not under biological therapy and the impact of CD‐associated colorectal strictures on CRC development. The study hypothesis is that the use of biological therapy in the control of CD activity may decrease the risk of developing CRC.Study design and settingAn international, retrospective, snapshot of the prevalence of CRC in patients with CD, reported according to the SPIRIT guidelines. The study will involve centres that hold regular IBD multidisciplinary team meetings and have both IBD colorectal surgeons and gastroenterologists. Each participating centre will provide a local consultant lead and a local trainee lead. Data will be collected within a 2‐year recruitment period (January 2017–January 2019).Study populationAdult patients who presented with CD during the study period. Patients with an incidental diagnosis of CD during evaluation for CRC will be excluded.Statistical planBaseline patient characteristics will be summarized using the appropriate descriptive statistics. Univariable, multivariable and Cox regression models will be used to identify factors significantly associated with CRC. For noncontinuous variables a comparison between the subgroups will be carried out using the chi‐square test corrected by Fisher's exact test if appropriate. A p‐value of <0.05 will be considered statistically significant.Data storageData will be stored on a secured server, pin‐code protected according to the local data management agreement. 10.1111/codi.70005 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1111/codi.70005
format Artículo Open Access
id wiley_oa_10_1111_codi_70005
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit
Zoe Garoufalia
Sameh Hany Emile
Justin Dourado
Marylise Boutros
Richard Brady
Valerio Celentano
Justin Davies
Phillip R. Fleshner
Rachel Gefen
Stefan D. Holubar
Nir Horesh
Alaa El‐Hussuna
Deborah Keller
Amy Lightner
Gianluca Pellino
Sherief Shawki
Spyros Siakavellas
Antonino Spinelli
Janindra Warusavitarne
Steven D. Wexner
Colorectal Disease
Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit Zoe Garoufalia Sameh Hany Emile Justin Dourado Marylise Boutros Richard Brady Valerio Celentano Justin Davies Phillip R. Fleshner Rachel Gefen Stefan D. Holubar Nir Horesh Alaa El‐Hussuna Deborah Keller Amy Lightner Gianluca Pellino Sherief Shawki Spyros Siakavellas Antonino Spinelli Janindra Warusavitarne Steven D. Wexner Colorectal Disease AbstractBackgroundInflammatory bowel disease (IBD) affects more than 10 million people worldwide. Men and women are equally affected by Crohn's disease (CD). It has been shown that patients with CD are at an increased risk of a colorectal cancer (CRC) diagnosis and CRC‐related mortality. During the last two decades, biological therapies have revolutionized the treatment of CD. There are no current studies investigating the prevalence of CRC in patients with CD in the era of biological therapy and the possible features of patients with CD who are at high risk of developing CRC.AimWe aim to assess the prevalence of CRC, risk factors and profile of CRC in patients with CD receiving biological treatment compared with those who are not under biological therapy and the impact of CD‐associated colorectal strictures on CRC development. The study hypothesis is that the use of biological therapy in the control of CD activity may decrease the risk of developing CRC.Study design and settingAn international, retrospective, snapshot of the prevalence of CRC in patients with CD, reported according to the SPIRIT guidelines. The study will involve centres that hold regular IBD multidisciplinary team meetings and have both IBD colorectal surgeons and gastroenterologists. Each participating centre will provide a local consultant lead and a local trainee lead. Data will be collected within a 2‐year recruitment period (January 2017–January 2019).Study populationAdult patients who presented with CD during the study period. Patients with an incidental diagnosis of CD during evaluation for CRC will be excluded.Statistical planBaseline patient characteristics will be summarized using the appropriate descriptive statistics. Univariable, multivariable and Cox regression models will be used to identify factors significantly associated with CRC. For noncontinuous variables a comparison between the subgroups will be carried out using the chi‐square test corrected by Fisher's exact test if appropriate. A p‐value of <0.05 will be considered statistically significant.Data storageData will be stored on a secured server, pin‐code protected according to the local data management agreement. 10.1111/codi.70005 http://creativecommons.org/licenses/by-nc/4.0/
title Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit
topic Colorectal Disease
url https://onlinelibrary.wiley.com/doi/10.1111/codi.70005